AtheroGenics Atherosclerosis Therapy Licensed By AstraZeneca
This article was originally published in The Pink Sheet Daily
You may also be interested in...
Outlook For AstraZeneca/AtheroGenics’ Candidate May Sink On ARISE Trial Results
A Phase III clinical study evaluating the atherosclerosis candidate failed to meet its primary endpoint.
Outlook For AstraZeneca/AtheroGenics’ Candidate May Sink On ARISE Trial Results
A Phase III clinical study evaluating the atherosclerosis candidate failed to meet its primary endpoint.
AtheroGenics' AGI-1067 Pivotal Data Expected In Late Q1
Firm believes a low event rate in the Phase III ARISE trial could signal a therapeutic effect of the atherosclerosis candidate, in development with AstraZeneca.